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The aim of this thesis is to study the osmotic properties of model infusion solutions 
of sodium chloride and potassium chloride. In a concentration range of 0.01 – 
1,00mol/kg, density at 20°C and osmolality is measured. The average values of 
density at 20°C and/or osmolality are used to convert molality to molarity and 
osmolality to osmolarity, respectively. The average partial specific volume and the 
average molal volume of the dissolved solute 0.29 ml/g and 16.80 ml/molwas 
estimated experimentally for sodium chloride. For potassium chloride, the average 
volumes are 0.36 ml/g and 26.84 ml/mol, respectively. 
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2 The aim of study 
In the theoretical section, the aim of this thesis is to present the general information 
about the parenteral preparations, their formulation and quality requirements. 
Particularly, the osmotic properties of infusions are studied. 
In the experimental part, the aqueous solutions of sodium chloride and potassium 
chloride in a concentration range of 0.01 – 1,00mol/kg are prepared and their density 
and osmolality is measured. The results are used to convert molality to molarity as 
well as osmolality to osmolarity, to estimate the partial specific volume and the 





3 List of abbreviations 
Symbol Unit Meaning 
cos mOsmol/l Osmolarity 
mos mOsmol/kg Osmolality 
c mol/l Molarity 
m mol/kg Molality 
M0 g Mass of solute 
M g Mass of solution 
d g/ml Density  
Vw ml Water volume 
Vg ml/g Partial specific volume 
Vmol ml/mol Molal volume 
C g/ml Concentration 




Parenteral preparations are dosage forms of drugs that are injected directly to body 
tissue usually through the skin or mucous membranes, in different routes of 
administration. Since the drugs are directly injected to the body tissue they must be 
pure, isotonic, free from various types of contaminants, and compatible with other 
substances that might be needed to be applied together. Administration of parenteral 
dosage forms might be required for various reasons such as patient incompliance or 
inactivation of the active substance in the gastrointestinal tract (GIT), although they 
might have some disadvantages. That being said, production of parenteral 
preparations is a big responsibility and their administration requires caution and 
control (Troy, 2005). 
The aim of this thesis is to study the methods that are being used for the whole 
production process (including sterilization and shelf-life) of large volume parenteral 
products, according to their type and use, and focus on electrolyte solutions and their 
properties. Also the importance of the osmotic properties (especially of osmotic 
pressure) to the human body is going to be expressed. And finally, in the last part of 
this document are going to be displayed in graphs the relationships between molality 
and some other important values such as: partial specific volume, molal volume, and 
molal osmotic coefficient; the conversion of osmolality to osmolarity is also going to 
be explained. 
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5 Theoretical section 
5.1 Parenteral Preparations 
There are some general factors that need to be taken into consideration when 
developing a parenteral drug. Those factors determine the drug dosage form and its 
formulation. Such factors are: the route of administration, the pharmacokinetics of 
the drug, the compatibility of the drug with other “co-substances” when administered 
together, and the drug solubility and stability. 
The route of administration may vary and includes many different ways. Parenteral 
drugs can be injected different ways such as subcutaneously, intramuscularly, 
intravenously, intra-arterially, intrathecally, and intradermally. The dosage form of 
the drug usually determines its route of administration (i.e only 
microheterogenousemulsions o/w or solutions can be administered intravenously). 
The pharmacokinetics of the drug also determine the dosage form as well as the 
route of administration. The rates at which the drug is being absorbed, distributed, 
metabolised and excreted, can be modified in order to become more rapid or 
retarded. It should be mentioned that these rules do not apply for intravenous or 
intra-arterial routes of administration. 
The compatibility of the drug with other “co-substances” is very important. It is 
possible that an excipient added to the formulation of the parenteral preparation will 
help the drug‟s action in one way and at the same time create a problem at the drug‟s 
action in a different way. For example the added “co-substance” may stabilize 
chemically the drug and at the same time catalyse some other reactions, that degrade 
the drug (i.e chemical degradation or oxidative degradation). 
Last but not least, drug solubility and drug stability must be taken into 
consideration when developing the formulation of a parenteral preparation. Solubility 
indicates the appropriate concentration of the drug in the dosage form. In the case 
where the drug is not soluble enough in a specific dosage, then substances that 
increase the drug‟s solubility need to be added. Sterile solid dosage forms need to be 
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created if the drug appears stability issues. Stability is also related to the expiration 
date of the drug andalso to its storage conditions (Troy, 2005). 
5.1.1 Excipients in small volume parenterals (SVPs) 
In order to achieve safety and efficacy of parenteral products many times various 
substances should be added into the formula to maintain pharmaceutical stability of 
the product, ensure its sterility or to aid in parenteral administration. Such substances 
are antioxidants, buffers, bulking materials, chelating agents, inert gases, solubilizing 
agents and protectants. In such preparations it is important to choose added 
substances that are accepted by regulatory agencies throughout the world. 
 
As antioxidants in aqueous parenterals, thesubstances that are most frequently used 
are salts of sulphur dioxide, including bisulphite, meta-sulphite and sulphite.These 
manage to maintain the stability of the drugs by being preferentially oxidised and 
gradually consumed over the shelf life of the product. It is possible that sulphites 
cause allergic reactions in some asthmatics. In this case it would be better to consider 
alternative use of antioxidants or to manufacture and pack the product in such a way 
in order to eliminate or to minimize the concentration of bisulphite required. 
 
Many times a certain pH is required to maintain the stability of the drug and also 
solubility is strongly dependent on the pH of the solution. In order to achieve and 
maintain specific pH values, buffers are added into the solutions and that is why 
SVPs should be formulated in such way in order to have sufficient buffer capacity. 
Buffers for parenterals usually consist of either a weak base and the salt of a weak 
base or a weak acid and the salt of a weak acid. Last but not least, factors that 
influence the pH value of the product are the product degradation, diffusion of gases 
(through the closure), and container and stopper effects. 
 
Chelating agents are also used to inactivate metals that generally catalyse oxidative 
degradation of drug molecules. Sources of metal (copper, iron, zinc) contamination 
 12 
include raw material impurities, solvents (i.e. water), manufacturing equipment and 
rubber stoppers and containers. 
Another way of protecting the oxygen-sensitive medicaments is by displacing the air 
in the solution with nitrogen or argon. Reducing the dissolved oxygen by boiling the 
water or by purging with nitrogen makes this technique more effective. 
 
Surfactants and solubilizing agents are also used as excipients in small volume 
parenterals. Solubilizing agents are added to increase drug solubility and it is 
recommended that their effect on the safety and stability of the drug, must be 
considered. Surfactants are surface active agents that are used to disperse a water-
insoluble drug as a colloidal dispersion. They prevent crystals from growing in the 
suspension and they are also used for wetting of powders in order to provide 
acceptable syringability. 
 
Other important excipients that are added in injectable solutions, especially small 
volume preparations, are tonicity adjustment agents. It is very important for such 
preparations (intravenous) to be isotonic. It is a fact that the osmotic pressure 
changes and as a result, an exchange of ionic species across red blood cell 
membranes, non-isotonic solutions occurs. Especially if given in volumes larger than 
100 ml, hypotonic or hypertonic solutions can lead to hemolysis or crenation of red 
blood cells, respectively. In context to the large volume preparation, the tonicity and 
osmoticity will be referred later in this thesis. 
 
Protectants are also another type of excipients, which are added into a parenteral 
formulation to protect against loss of activity caused by some stress, from the 
manufacturing process. They can also prevent loss of active ingredient by packaging 
materials or by adsorption to process equipment.Attention should be given to 
packaging materials, rubber closures and other polymeric materials. They should be 
carefully examined for adsorptive potential; especially for intravenous infusions 
where most of the materials used (i.e. plastic bags, infusion sets, inline filters) are 
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polymeric. Human serum albumin (HAS) is used as protectant against adsorptive 
loss of proteins which may occur at lower concentrations. It prevents the adsorption 
of the drug by being preferentially adsorbed while coating the surface of interest and 
by being present at higher concentration (Florence and Siepmann2009). 
Some examples of protectants are cryoprotectants and lyoprotectants and they are 
used to inhibit loss of the drug integrity resulting from freezing or drying, 
respectively. They also tend to improve the stability of proteins against inactivation 
by thermal denaturation. 
 
All multiple-dose parenteral products should contain a suitable preservative system 
like antimicrobial agents, in bacteriostatic or fungi-static concentrations. They must 
be contained in adequate concentration when they are about to be used in order to 
prevent multiplication of microorganisms that were introduced into the preparation 
while withdrawing a portion of the contents with a hypodermic needle and syringe. 
However, the inclusion of preservatives can be a difficult challenge because of the 
viewpoints concerning which agents are acceptable to be used and when it is 
appropriate to include them in a formulation. Because of the fact that antimicrobial 
agents might be toxic for the patient, there are usually prescribed some maximum 
volume and concentration limits, particularly for those that are being frequently used 
in parenteral products.  
Another task that the scientist will have to deal with while using antimicrobial agents 
is their interactions with other components of the formulation that could reduce the 
efficacy of the agents. It is also common that a particular agent will be effective in 
one formulation, but ineffective in another. For these reasons preservative efficacy 
testing should be done on each formulation they are used, to assure the effectiveness 
of the used concentration (Florence and Siepmann 2009; Troy 2005). 
Despite all the challenges and difficulties that may occur while developing multi-
dose formulations with antimicrobial preservatives, they offer several advantages 
such as: minimization of product wastage because different size doses may be 
obtained from the same container; also the same container may be used over a period 
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of time without the concern for microbial growth and last but not least the packaging 
is minimized because multiple doses are supplied in a single container. 
Examples of the eight most commonly used antimicrobial preservatives are benzyl 
alcohol, chlorobutanol, m-cresol, methylparaben, phenol, phenoxyethanol, 
propylparaben, and thimerosal. Phenol and benzyl alcohol are more specifically used 
primarily in peptide and protein parenteral products. However, benzyl alcohol has 
been demonstrated to bind to and accelerate aggregation of proteins (associated with 
protein conformational denaturation or instability). Another example that was 
mentioned above, parabens, have a broad spectrum of antimicrobial activity at pH 4-
8, but they are mainly used against yeasts and molds (Meyer et al, 2007). 
5.1.2 Vehicles for parenterals 
The most widely used vehicle for parenteral preparations, is the water for injection 
(WFI). WFI must be pure and pyrogen-free and that must be ensured while 
producing and storing it. WFI is usually obtained by distillation of deionized water 
and it is the only method that is permitted by the European Pharmacopoeia (EP), 
while the United States Pharmacopoeia (USP) and the Japanese Pharmacopoeia (JP) 
also permit reverse osmosis for its production.  
Usual contaminants that are found in the water are microorganisms, dissolved 
organic and inorganic compounds, and foreign substances. Organic substances can 
be removed by charcoal beds while particulate contaminants can be removed by 
membrane and depth filters and inorganic compounds are usually removed 
deionization, reverse osmosis, distillation or a combination of the above methods. 
Last but not least microorganisms are reduced by filtration, recirculation of water, 
chilling or heating preventing by this way pyrogen to be formed that would have 
occurred in a static deionization system (Florence and Siepmann 2009). 
 If the WFI is going to be stored for more than 24 hours then it must be stored at 
temperatures like 5Cor from 60C to 90C, in order to inhibit microbial growth. The 
USP also lists bacteriostatic WFI and sterile WFI. These must be sterile unlike WFI. 
Because of the possibility of glass leaching into the product during subsequent 
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storage and high-temperature sterilization, higher levels of solids are allowed in these 
vehicles. In order to prevent the administration of large quantities of bacteriostatic 
agents, bacteriostatic WFI should not be stored in containers larger than 30 ml 
(because if bacteriostatic agents are administered in large volumes, they can become 
toxic). 
Solvents that are being used, other than the aqueous (i.e. water, ethanol in small 
volume parenterals), are the non-aqueous (i.e. soybean oil, safflower oil) and the 
mixed (aqueous/non-aqueous) ones. The last two may be necessary to stabilize drugs 
that are hydrolyzed by water or to improve their solubility. Non-aqueous solvents 
must be carefully screened and tested to make sure that they are non-toxic, non-
irritating, they exhibit no pharmacological action and that they are stable and 
compatible with all the ingredients of a formulation (Florence and Siepmann 2009). 
5.1.3 Large-Volume parenterals (LVPs) 
Large-volume parenterals are pyrogen-free, sterile, aqueous solutions or emulsions 
with water as the continuous phase. They are usually made isotonic with respect to 
the blood and they are intended to be administered by intravenous infusion to 
replenish body fluids or electrolytes or to provide nutrition. They are administered in 
large volumes (100ml to 1000ml or more) per day by slow intravenous infusion and 
they are packed in large single-dose containers. Because of the large volumes they 
are being administered, they must not contain any antimicrobial preservatives or 
other pharmaceutical additives and when examined under suitable conditions of 
visibility they should be clear and free from particles. Electrolytes, vitamins and 
antineoplastics are frequently incorporated into large-volume parenterals for co-
administration to the patient (Allen et al, 2005; Eur. Pharm. 8.0). 
5.1.4 Types of LVPs 
Large volume parenterals are designed in such way in order to provide electrolytes, 
fluid (water), carbohydrates (dextrose solutions) and some other uses that are going 
to be described below (Florence and Siepmann 2009). 
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Hyper-alimentation solutions are administered to patients intravenously, to provide 
them with large amounts of nutrients (i.e. carbohydrates, lipids, proteins and 
vitamins) in order to maintain them (also known as maintenance therapy) because 
they are unable to take food orally for several weeks (i.e. for amounts of 
4000kcal/day or more). 
Dextrose is the most commonly used carbohydrate, especially in high concentrations 
such as 20%; small amounts of fructose, alcohol and sorbitol can also be present in 
some products (dextrose solutions are all hypertonic and together with amino acid 
mixtures they exert the greatest effect on the osmolarity of the compounded product). 
In some special cases even insulin is provided. Providing large amounts of dextrose 
increases the solution‟s caloric value while at the same time keeps the volume that is 
required to be administered, to the minimum. Such solutions are administered slowly 
through a large vein i.e. the superior vena cava. This way, not only the rapid dilution 
of the concentrated hyper-alimentation fluid is achieved, as well as the risk of tissue 
or cellular damage due to hyper-tonicity of the solution, is minimized. In general, 
solutions that contain no more than 10% of dextrose can be administered 
peripherally, while those that contain more than 10% dextrose should be 
administered via the superior vena cava. 
Sodium, potassium, magnesium, calcium, chloride, phosphate, and bicarbonate are 
some examples of the essential electrolytes that are used in relatively large amounts 
(Florence and Siepmann 2009; Allen et al, 2005). 
Some examples of peptides and proteins that are being used in such drug 
formulations are the following: antivenin, desmopressin acetate, interferon alfa-n3 
(derived from human leukocytes), insulin aspart (recombinant), insulin glargine 
(injection of rDNA origin), and epoetinalfa. Calcitonin-salmon injection (synthetic), 
etanercept, and sargramostim (recombinant) are used as well (Meyer et al, 2007). 
Oil-in-water emulsions are heterogenous systems in which one liquid (internal phase) 
is dispersed throughout another (external or continuous phase) and they can offer a 
delayed absorption of the total dose, for drugs with large partition coefficient. 
Emulsions can solve problems such as insufficient drug solubility in water, or 
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hydrolysis of drugs. Similarly to all parenteral preparations, emulsions must meet 
many requirements regarding physic-chemical and biological stability, freedom from 
endotoxins, sterilization etc. A unique characteristic of parenteral emulsions is that 
they have strict requirements for globule size, as this has a direct effect on their 
stability and toxicity and it is directly affected by the oil concentration. The most 
frequently used globule sizes, are less than 1.0 – 2.0 μm, while sizes in the range 0.5 
– 1.0 μm are utilized more rapidly by the body. Globule sizes higher than 4.0 – 6.0 
μm are known to have an increased risk of causing emboli and changes in blood 
pressure. Once the emulsion is formed, it is necessary to reduce the globule size by 
using high-pressure homogenizers or microfluidizers. The oils that are being used for 
such preparations are either long-chain triglycerides (LCTs) obtained from vegetable 
sources (i.e. soybean oil, safflower oil, sesame oil, corn oil, castor oil etc.) or 
medium-chain triglycerides (MCTs) derived from re-esterification of fractioned 
coconut oil fatty acids. Emulsifiers that are being used are of either natural (derived 
from egg yolk or soybean oil) or synthetic (i.e. nonionic materials such as Pluronics 
– poloxamers or polyoxyethylene/polyoxypropylene derivatives-) origin. Despite the 
fact that natural emulsifiers may cause some allergic reactions, they are most 
frequently used because of their relative safety and stability. The synthetic ones are 
less frequently used, and mainly for small-volume parenterals because when used in 
large-volume parenterals or for long administration they can lead to “overloading 
syndrome” (Floyd, 1999). 
It is important to mention that for the formulation of emulsions, the water soluble 
components are dissolved or dispersed in the aqueous phase first. Then the emulsifier 
can either be dissolved in the oil phase or dispersed in the aqueous phase. 
Antioxidants and lipophilic drugs are usually dissolved or dispersed in the oil phase 
(Floyd, 1999). 
This is generally known as total parenteral nutrition (TPN) and should allow for 
anabolism, tissue synthesis and generally to maintain homeostasis in the body. This 
kind of formulations usually consists of dextrose mixtures, amino acids and lipids 
(i.e. soybean oil, safflower oil etc.), containing added trace metals, vitamins and 
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electrolytes. This method is applied to comatose patients or patients that undergo 
treatment for gastrointestinal tract diseases (including cancer), esophageal 
obstruction, ulcerative colitis, anorexia nervosa etc. and it is life-saving or life 
sustaining. Parenteral nutrition is also used from times to times in order to prepare a 
malnourished patient for surgery, chemotherapy or radiation therapy; and it is also 
used in patients with renal or hepatic failure. Long-term parenteral nutrition is also 
used in patients that have insufficient gastro-intestinal tissue for adequate digestion 
and absorption of nutrients, resulting from a surgery or a disease.It is used in 
patient‟s home (home parenteral nutrition, HPN) (Florence and Siepmann 2009). 
 
Cardioplegia solutions are another type of LVPs used in heart surgery to prevent 
ischemic injury to the myocardium when the blood supply to the heart is clamped 
off. They are also used during reperfusion and to maintain an operating field free 
from blood as well as to make the myocardium flaccid. These are usually 
formulations that contain electrolytes, the composition of whose is intended to 
maintain diastolic arrest. Cardioplegia solutions are usually administered cold in 
order to minimize the metabolic activity and to cool the myocardium, after being 
admixed. They are usually hypertonic to minimize reperfusion injury (usually 
resulting from some tissue edema) and slightly alkaline to compensate for metabolic 
acidosis (Florence and Siepmann 2009). 
 
The sterile peritoneal dialysis solutions are infused into the abdominal cavity, 
continuously, to clean the peritoneum and afterwards they are being continuously 
withdrawn. The peritoneum acts as a dialysis membrane for the exchange between 
the blood and dialysis solution. Those solutions aim to remove toxic substances from 
the body or to accelerate or aid the normal function of kidneys to excreting such 
substances. They also correct electrolyte imbalance, and eliminate fluid overload. 
This way they treat acute renal insufficiency as well as cases of drug or chemical 
toxicity. Their main content is dextrose and they are ionically similar to extracellular 
fluid. Toxins and metabolites are being removed by diffusing into the dialysis fluid 
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through the peritoneum. Antibiotics are commonly added into these solutions as a 
prophylactic measure (Florence and Siepmann 2009). 
Last but not least peritoneal dialysis solutions do not restrict the patients on their diet 
or their fluid intake. Once the patients‟ electrolytes and fluids are corrected, they 
remain fairly constant and there is no significant anemia or blood loss. Only some 
protein might be lost through the peritoneum during dialysis, but this loss might be 
increased in case of peritonitis. Peritoneal dialysis solutions must be sterile and 
pyrogen-free. Since the peritoneal infection can be a recurrent problem, the patients 
must use strict aseptic techniques when exchanging the bags. 
 
For irrigating, flushing and cleansing body cavities and wounds, irrigating solutions 
are being used. Because of the fact that these solutions are applied topically, they are 
not considered to be parenteral preparations. They are still considered large volume 
preparations though, and it is important to be mentioned. They must be sterile and 
pyrogen-free. These solutions are also used for surgical purposes (urological 
irrigating solutions). They remove blood and maintain tissue integrity during an 
operation. The water that is used for irrigation solutions is sterilized distilled water 
free from pyrogen and it is meant for a single use only. The container where it is 
packed is sealed and sterilized by moist heat. 
Blood products are also commonly packed as sterile large volume parenteral fluids 
despite the fact that they are not considered to be large volume parenteral 
preparations. These products include albumin, human plasma and blood protein 
fractions. All these products must be treated with specialized heat or filtration, in 
order to inactivate virus contamination prior to packaging. Since these products are 
unstable to heat sterilization, they are filter-sterilized and then aseptically filled into 
containers (Florence and Siepmann 2009; Chapman 2009; Lund1994). 
5.1.5 Uses of LVPs 
Large volume parenterals are used in patients that are recovering from a surgery (or 
entering one) because they are unconscious or unable to take fluids, nutrition or 
electrolytes orally. They are also used in patients who have suffered a great loss of 
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electrolytes and fluid. These two types are also known as maintenance therapy and 
replacement therapy, respectively. 
 
Maintenance therapy is usually employed when the patients are unable to receive 
nutrition or fluids orally for longer periods; this total parenteral nutrition is 
described in details earlier in this text (chapter 5.1.5).  
It is recommended when infusing central or peripheral TPN solutions to use a filter 
in order to avoid precipitations that can cause serious hazards to the patient‟s health, 
such as pulmonary emboli caused by calcium phosphate precipitation. An example of 
such filter is a 0.22 μm filter that contains both bacterial-retentive and air-eliminating 
filters, and it is used in lipid-free (two-in-one) parenteral nutrients solutions. Two-in-
one parenterals are used as an alternative to three-in-one admixtures, when using 
lipid emulsions (because they obscure any precipitate). In such case, lipids are 
infused separately into the two-in-one admixtures via a Y-site. 
 
Replacement therapy is employed when the patient has suffered from severe 
diarrhea or vomiting greater than usual, and has lost great amounts of fluids and 
electrolytes. Patients with burns, trauma, Crohn‟s disease or AIDS are candidates for 
this type of therapy. 
 
The daily water requirement, in normal adults, is the amount that is needed to 
replace normal and expected losses (i.e. losses from urine, feces, skin and 
respiration). Normal „daily water requirement‟ values for adults are about 25 to 40 
ml/kg of body weight. In water replacement therapy for adults, 70 ml/kg/day might 
be required in addition to water maintenance requirements. However, in order to 
avoid fluid overload, especially in patients with cardiovascular or renal disorders and 
in elderly, monitoring of their blood pressure is recommended. Administering water 
intravenously in such way may lead to osmotic hemolysis of red blood cells. To 
avoid this phenomenon and protect the red blood cells from hemolysis, water is 
generally administered as a solution with dextrose or electrolytes with sufficient 
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tonicity (because patients that require water, generally require nutrition and/or 
electrolytes). 
 
For patients with electrolyte requirement, sodium, the primary extracellular cation 
and potassium, the principal intracellular anion, are most frequently administered. 
Sodium is very important for maintaining extracellular fluids. It is conserved from 
the body when it is lost or removed from the diet. Negative sodium balance, when 
sodium levels are low, can be prevented by administering 3 to 5 g of sodium chloride 
to the patient. Low sodium levels in the body can be a result of excessive sweating, 
diarrhea or use of some diuretics. That can lead to muscle weakness, fatigue, 
apprehension and convulsions.  
On the other hand, sodium levels can increase when the person suffers from some 
kidney impairment or if the person does not drink enough water (especially in hot 
weather). Symptoms of elevated sodium levels can be dry and sticky mucous 
membranes,flushed skin, thirst, lack of tears and elevated body temperature. High 
blood pressure is caused in 20% of the cases from sodium excess as well.  
Sodium is usually paired with chloride, the primary extracellular anion. The 
importance of chloride is also significant, as it maintains the acid-base balance of the 
extra-cellular fluid, the fluid levels balance inside and outside the cell, and it also 
plays an important role in muscle contraction. Last but not least chloride is necessary 
to prevent bicarbonate from “moving” the acid-base balance towards the alkaline 
side.  
 
Potassium is very important for maintaining normal cardiac and skeletal function. 
The usual daily potassium intake is about 100 mEq and the usual daily loss is about 
40 mEq, so any replacement therapy should include at least 40 mEq plus the amount 
that is needed to replace the additional losses.  
Potassium can be lost through several ways such as repeated enemas, excessive 
perspiration, different kinds of traumas, some gastrointestinal tract impairment, 
uncontrolled diabetes, surgery, and the use of some medications like loop diuretics 
 22 
and thiazide. Some other reasons for low potassium levels might be anorexia 
nervosa, very low-calorie diets, or acute alcoholism because the patients are not 
taking in enough of it. General weakness, weak pulse, falling blood pressure and 
faint heart sounds are just some of the symptoms of low potassium levels in the 
organism. Severe potassium loss can even lead to death.  
On the other hand, abnormally high potassium levels may cause diarrhea, pain, 
muscle cramps and irritability. Elevated potassium levels can be a result of excessive 
potassium-rich food consumption, or kidney failure. Other reasons for hyperkalemia 
may be potassium supplements, angiotensin-converting enzyme inhibitors, as well as 
the potassium-sparing diuretic therapy.  
In severe potassium deficiency situations, intravenous electrolyte replacement with 
potassium chloride is usually employed. The amount as well as the infusion rate of 
the potassium chloride in the solution must be carefully checked; it must be carefully 
diluted with a large-volume parenteral solution, mixed well and administered by 
slow intravenous infusion. They must not be given undiluted, because this might lead 
to death. Last but not least, for patients in need of aggressive potassium replacement, 
the potassium serum level should be assessed every 6 hours during the early phase of 
therapy and later once normal potassium serum levels are achieved, it can be 
administered once per day. 
 
In order to fulfill the caloric requirements, estimated by body weight, of patients 
that are undergoing maintenance or replacement therapy, a 5% dextrose is given to 
them. The use of dextrose is also minimizing ketosis as well as the protein 
breakdown. 
 
Sometimes, although it is not recommended, it is necessary to administer medication 
in combination with the parenteral nutrition to ensure that the patient is receiving 
adequate nutrition as well as appropriate drug therapy. This mainly applies for young 
patients, who have a limited fluid capacity usually caused by some disease (i.e. renal 
insufficiency or congestive heart failure) and limited vascular access. It is also true 
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that administering the medication in combination with the parenteral nutrition rather 
than interrupting the feeding in order to administer the medication, makes the 
rebound hypoglycemia less likely. However, this practice has also some risks such as 
catheter sepsis and occlusion (Allen et al, 2005). 
 
5.1.6 Sterilization methods 
Sterile dosage forms have some standard characteristics that distinguish them from 
other dosage forms like the non-sterile. They must be safe, sterile, free from pyrogen 
contaminants, free from visible particulate matter, stable, compatible and isotonic 
(Florence and Siepmann 2009). 
All those seven characteristics will be described in more detail in the following 
chapter (5.1.8). For sterilization five methods are usually used: steam, dry heat, 
filtration, gas, and ionizing radiation. They are mainly used for parenterals, although 
gas and ionizing radiation are mainly used for devices and surgical 
materials.Therefore, gas and ionizing radiation are not going to be mentioned in this 
chapter, since this text is mainly focused on the parenteral solutions, and not on the 
devices used for them. 
 
Autoclave steam sterilization is a method that is being preferred when the solutions 
and the containers are able to withstand the autoclaving conditions, and it is used 
mainly for aqueous solutions. The main reasons are that moist heat sterilizes quickly 
as well as inexpensively. It is important that the solution and the container are 
permeable to steam though (i.e. oils and tightly closed containers are normally hard 
to sterilize by steam). 
The use of steam sterilization has increased with the widespread use of flexible 
packaging for LVPs. In contrast to the traditional LVP glass bottles that are tightly 
closed with rubber stoppers, the flexible plastic LVP containers offer some 
advantages, regarding the autoclave sterilization. More specifically, they offer a 
larger surface area for heating per unit volume of liquid. Also, shorter heat-up and 
cool-down periods are required. Due to the net effect, LVP products that are packed 
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in flexible containers are allowed to have a shorter sterilization cycle, and by a 
shorter sterilization cycle, LVPs are exposed to less heat, having this way less 
potential to degradation. The manufacturing costs are also reduced. At last, if they 
are held in a “flattened” position during sterilization, then the heat penetration depth 
that is required is reduced, having as a result a more uniform thermal mapping of 
contents. 
 
Another way of sterilizing, is sterilization by dry heat. This method has a good 
penetration power and is not as corrosive as steam. It is primarily used in powders 
and oily preparations. In contrast to steam sterilization, this method has a slow heat-
up time, making long sterilization periods at high temperatures unavoidable.  
The two principal methods of dry-heat sterilization are convection hot air and 
infrared. Convection hot-air sterilizers are usually heated electrically and are of two 
types: mechanical or gravity. In gravity convection units there is a need to promote 
uniformity of heat distribution throughout the chamber. In order to achieve that, a fan 
is used (Florence and Siepmann 2009). 
Infrared rays on the other hand only sterilize surfaces. This method kills 
microorganisms mainly through oxidation. The amount of moisture that will be 
available to assist the sterilization in the dry-heat units varies in different locations of 
the chamber and at different time intervals within the cycle. Also the heat that will be 
available, its diffusion, and the environment at the air/spore interface can influence at 
some extent the kill rate of the microorganism. For this reason cycles tend to be 
longer and hotter to make sure that the varying conditions mentioned above will not 
invalidate a run. 
 
Sterilization by filtration has become sufficiently reliable only in the past 30 years 
in order to be used on a wide scale to sterilize injectable solutions. The filters that are 
being used are of two basic types: depth and membrane.  
Depth filters aim to retain particles and microorganisms through a combination of 
tortuous pathway and adsorption. Materials that are used to make such filters are 
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inorganic fibers, diatomaceous earth, natural fibers, and porcelain. Their biggest 
advantage is that they can retain very large quantitiesof particles. However, they also 
have disadvantages such as grow-through and reproduction of microorganisms, 
tendency of the filter components to slough during line surges, and also retention of 
some liquid in the filter. 
Membrane filters on the other hand rely on sieving and absorption to prevent 
particles from passing, and their use has been widespread the last few years. These 
filters are also made from a variety of materials, although the most common ones are 
made of cellulose ester derivatives. Major advantages of membrane filters are no 
product retention, no media migration and efficiency that it is not dependent on low-
rate pressure differential. Their disadvantages are low capacity before clogging and 
the need to remove surfactants by prewashing. 
According to the advantages and disadvantages of both types, it is common to use a 
depth filter to remove the great majority of particles and afterwards to use a 
membrane filter in order to remove the remaining particles and microorganisms 
(Florence and Siepmann 2009). 
 
5.1.7 Characteristics of sterile dosage forms 
Sterile dosage forms have seven primary characteristics that make them unique 
pharmaceutical preparations. Those primary characteristics are going to be described 
below, in this chapter (Akers, 2005; Ph. Eur.8.0 2013). 
 
Safety is the first to be mentioned as sterile dosage forms are mainly injected directly 
into the body, avoiding this way the body‟s barriers for anything that could be 
harmful to the body. For this reason, any compound to be injected into the body must 
be approved for its safety at the quantity that it is going to be injected (since any 
compound injected in large amounts can be unsafe). The formulation of sterile 
dosage forms is more difficult than the formulation of non-sterile dosage forms. That 
is because when it is needed to overcome a problem related to drug stability, 
solubility, tonicity etc. the requirement for safety prohibits the use of many effective 
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substances while for non-sterile dosage forms it is not necessary to restrict the 
options regarding to safety. Most pharmaceutical preparations are required to be 
tested for safety in animals, especially biological products, in order to provide 




Sterility is obviously what defines a sterile product. It is one of the greatest 
challenges to achieve and maintain sterility for such dosage forms. Sterility is 
achieved via various valid sterilization procedures for all components while 
manufacturing of the product, aseptic filtration, sterile environment where the 
products are being manufactured, use of antimicrobial preservatives for multiple-
dose products, validation of aseptic processes and valid testing for sterility of the 




Manufacturing a pyrogen-free product is very important since pyrogens are 
responsible for causing fever, and they originate mainly from microorganisms. In 
sufficient amounts they can also cause various complications to the human body and 
that is why all injectable products in the market must meet the requirements for 
pyrogen limits. Depyrogenation methods are rather complicating and they include 
cleaning validation, validated depyrogenation methods for glassware, time 
limitations, use of endotoxin-free materials, validated water systems, and removal of 
endotoxins from rubber closures (Akers, 2005). 
 
Visible particulate matter has an impact on product quality and perhaps safety as 
well. Both ready-to-use and reconstituted solutions must be free from visible 
particulate matter and must meet the specifications for numbers of sub-visible 
particles no greater than specific sizes, usually no greater or equal to 10 μm or no 
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greater or equal to 25 μm (Akers, 2005; Ph. Eur.8.0 2013). Similarly to other sterility 
characteristics, the presence or absence of visible particulate matter depends on 
several factors. Such factors include valid cleaning methods and solution filtration 
procedures, adequate training of personnel in manufacturing and control of 
production, and testing of the products for both visible and sub-visible particulate 
matter. 
 
Stability requirements apply for all dosage forms. All dosage forms must be stable 
under predetermined conditions during manufacturing, packaging, storage and usage. 
Both chemical and physical stability must be maintained throughout the shelf life of 
the product. Achieving and maintaining chemical and physical stability is the 
greatest challenge for the scientists developing sterile dosage forms; mainly the 
therapeutic peptides and proteins, because they are much more complicated chemical 
structures and they are more vulnerable to environmental conditions (i.e. pH, 
temperature, light, metal impurities etc.) (Akers, 2005). 
 
Sterile products must be compatible with diluents for reconstitution and diluents for 
infusion. And since many infusions contain more than one drug (i.e. small volume 
parenterals) that means that all the drugs in the infusion must be compatible with 
each other. Despite the fact that most of the drugs do not require any manipulation 
prior to administration, there are still some sterile dosage forms that need to be 
manipulated either by the patient or by the health care professional. Such example 
are the freeze-dried products that need to be reconstituted by sterile dilution, 
withdrawn into a syringe and later they are usually combined with a large volume 
parenteral fluid in order to be ready for administration.  
 
In ideal conditions any injected formulation should be isotonic with the human cells 
in order to avoid problems such as cell bursting (if the solution is hypotonic) or cell 
shrinking (if the solution is hypertonic). Large volume intravenous preparations and 
small volume preparations (administered in a way other than intravenously), must be 
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isotonic in order to avoid tissue irritation, pain and many other physiological 
reactions. Small volume injections do not have to be isotonic (although it would have 
been preferable) because small volumes do not damage a great amount of red cells 
that cannot be replaced. The ability of some solutes to dissociate into more than one 
species can explain the difference in isotonic concentrations among various large-
volume solutions. For nonelectrolyte solutions that exist as a single entity (i.e. 
dextrose), it is true that their osmotic pressure is proportional to the concentration of 
the solute. On the other hand for electrolyte solutions that can be dissociated into two 
ionic species (i.e. sodium chloride), it is true that their osmotic pressure would be at 
least twice that of a solution containing a nonelectrolyte (Akers, 2005). 
5.2 Osmosis & Osmotic properties 
Osmotic effects play an important role in maintaining the homeostasis (equilibrium 
in body regarding the chemical composition of fluids and tissues as well as various 
body functions i.e. blood pressure, heart rate etc.). It is not easy to measure these 
effects because they occur within or between cells and tissues (Allen, 2013). 
Osmosis can be expressed as a movement of solvent molecules through a partially 
permeable membrane (permeable to the solvent, but not the solute) from regions of 
lower solute concentration to regions of higher solute concentration, resulting to the 
equilibrium of the solute concentrations on the two sides. The pressure that is 
required to achieve and maintain this equilibrium, without any solvent movement, is 
defined as the osmotic pressure and is a very important parameter in all biological 
processes that involve fluid transfer, through biological membranes. An example of 
the importance of the osmotic pressure, is that its knowledge allows the practitioners 
to determine whether a parenteral solution is hyperosmotic, iso-osmotic or hypo-
osmotic (USP 35/NF 30 2011). 
5.2.1 Osmotic Pressure 
Each particle in a solution (regardless of its mass) exerts on average the same amount 
of pressure against the membrane. Thus, the osmotic pressure exerted by non-
diffusible particle of a solute in a solution, is determined by the number of particles 
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per unit volume of the fluid and not by the mass of the material. The osmotic 
pressure is a colligative property. This means that it depends on the number of 
particles and (molal concentration) in the solution. Particles can be un-ionized 
molecules, ions, macromolecules, or aggregates (i.e. a dimer). For ideal solutions 
where the solutes are non-dissociating (solutes and solvent do not interact with each 
other), the osmotic pressure πcan be estimated directly from the molality according 
to the following equation (USP 35/NF 30 2011): 
mTRd  )1000/(         (1) 
Where d is the density (kg/l), R is the ideal gas constant (8.314 KmolJ / ), T is the 
absolute temperature (
o
K) and m is the molality (mol/kg). For a real solution (non-
ideal behaviour), where the solute(s) is/are being dissociated the osmotic pressure 
can be calculated from the formula (USP 35/NF 30 2011): 
mmTRd   )1000/(        (2) 
Where d, R, T are as mentioned above, υis the number of particles formed after 
dissociation of one molecule (i.e. for NaCl υ=2), and Φm is the molal osmotic 
coefficient. It depends on the ionic characteristics of the solute, itsconcentration and 
its chemical properties. It can be experimentallydetermined by measuring the 
freezing point depression at different molal concentrations. Its value is less than one 
for concentrations of pharmaceutical interest and it decreaseswhen the molal 
concentration of the solute increases. From the equation (2) it can be seen that the 
factor that determines the osmotic pressure of a solution is the concentration of the 
solution in terms of number of particles and not in terms of the mass of the solute 
(USP 35/NF 30 2011). 
The osmotic pressure effects are very dynamic. For example the time that is required 
to achieve osmotic equilibrium between compartments in tissues, is usually just a 
few seconds (maximum a minute or two). For the body as a whole, more time is 
needed though. For example for a normal person it would require thirty to sixty 
minutes to achieve reasonably good osmotic equilibrium after drinking water. It is 
important to be mentioned that body fluids like blood and lacrimal fluid, normally 
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have an osmotic pressure which is described as corresponding to that of 0.9% 
solution of sodium chloride (Deardorff, 1980). 
 
5.2.2 Osmolality and Osmolarity 
It is very important to consider the concentration of solutes in osmotic relationships, 
when preparing large-volume parenteral preparations, because they are expected not 
to cause any undesired side effects on the body tissue. Intravenous fluids, in order to 
be safely applied into the body, they should be formulated with an osmotic pressure 
similar to biological fluids. This is largely determined by the osmotic effect of the 
dissolved solutes, and for this reason osmolarity should be listed on the labelling. 
The concentration of the osmotically active particles in a solution can be expressed 
either by osmolality mos(the osmolal concentration in Osmol/kg or mOsmol/kg) or by 
osmolarity cos (the osmolar concentration in Osmol/l or mOsmol/l).Osmolality, 
similar to the osmotic pressure, is directly connected to other colligative properties of 
a solution likevapour pressure lowering, boiling point elevation, and freezing point 
depression. It is true that the most accurate way of determining osmolality, is by 





osm          (3) 
Where ΔΤ is the freezing point depression measured in absolute temperature and 
mosthe osmolality as mentioned above in the text.  
In practice the measurement of osmolality is performed by an a special measuring 
device called osmometer, which consists of a means of cooling the container used for 
the measurement,a thermistor, a mixing device (vibrator) and a glass vessel where 
the sample to be measured is placed. Before the measurement the osmometer has to 
be calibrated.At the beginning,the cooling system is being started. And after a while, 
the mixing device (vibrator) is engaged at a temperature below the lowest 
temperature expected from the freezing point depression to prevent supercooling. 
The results of this measurement are given in mOsmol/kg by a digital readout (Knauer 
User‟s manual).  
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Osmolality is generally easy to determine in laboratory, however, osmolarity is the 
value that needs to be labelled in parenteral preparations. Osmolarity cos cannot be 
determined experimentally but it can be calculated theoretically, from the laboratory 
values of osmolality and from a method called “water content”. Some values that are 
required for such calculations are the density of the solutions, the volume of the 
solvent, and the partial specific volume of the solvent.  
The first method to calculate the osmolarity is the theoretical method according to 
the following equation: 
iios cc            (4) 
Where υ is the number of dissociating particles (i.e. υ=2 for sodium chloride, υ=2 for 
potassium chloride etc.), and c is the molarity in mol/l. However, large errors can 
occur from this equation even for relatively simple electrolyte systems. The more the 
concentration increases or more complex the system is, the more the possibility of 
error increases (20% or even more). This happens because the above equation (4) 
describes a solution with an ideal behavior where the particles do not dissociate and 
therefore do not interact with the solvent or with each other, which is not true for real 
solutionscontaining dissociating particles (Deardorff, 1980). 
Another way of estimating the osmolarity cos, is by using values such as the 
experimentally determined osmolality mos (mOsmol/kg), the also experimentally 











         (5) 
Where d is the density (g/ml), M0 is the mass of the substance (g), and Vgis the 
partial specific volume (ml/g). The partial specific volume of a solute is defined as 
the volume change of a solution when an additional 1g of a solute is dissolved in the 
solution.  
At last, one more method of measuring the osmolarity cos, is the method also known 
as “water content” method: 
)( Cdmc osos           (6) 
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Where d is the density (g/ml), and C is the total solute concentration (g/ml) (USP 
35/NF 30 2011). 
6 Experimental section 
6.1 Materials 
Sodium chloride (NaCl) (Ph. Eur. 6.2, Kulich Pharmas.r.o) 
Potassium chloride (KCl) (Ph. Eur 5.0, Kulich Pharmas.r.o) 
High quality distilled water for HPLC (Faculty of Pharmacy, Hradec Kralove) 
6.2 Equipment 
Moisture analyser, PRECISA 330 XM, Switzerland, d = 0.001 g 
Analytical balance, KERN ABJ 120-4M (Kern &Sohn GmbH), Germany, d = 0.0001 
g 
Electronicalbalance, ACCULAB Atilon ATL-4202-V, Sartorius Group, Germany, d 
= 0.01 g 
Density meter with oscillating U-tube installed (DMA 4100 M, Anton Paar, Austria) 
Osmometer(automatic semi-micro, Knauer, Germany) 
Eppendorf pipette (0-200μl, Eppendorf, Germany) 
6.3 Methods 
6.3.1 Preparation of solutions 
For the experiment I had to prepare solutions of sodium chloride and potassium 
chloride in molality concentrations: 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 
0.09, 0.10, 0.50 and 1.00 mol/kg each. To achieve those concentrations first I had to 
dry some amount of the substance to be used on moisture analyser, at 105
o
C for 30 
minutes.  
Then I measured different mass values for each substance on the analytical balance 
with precision of 0.0001g. Each measured mass of substancewas dissolvedin exactly 
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weighed1.00 kg of high quality distilled water and placed afterwards into closed 
bottles to prevent any evaporation.  
Later, I used the raw prepared samples for measurement of density and measurement 
of osmolality. 
6.3.2 Measurement of density 
For measurement of density the first step was to check the air/water density and 
temperature,at 20°C under the atmospheric conditions (15 minutes after the device 
was turned on). High quality distilled water was exposed to ultrasound in order to 
eliminate any possible gas that was “trapped” inside for 5 minutes.  
Afterwards each sample was measuredat 20°C, by introducing 1 ml the solution into 
the oscillating U-tube of the density meter with a syringe. This procedure was 
repeated 5 times for each one of the solutions. 
According to the instruction manual in the end of the measurements the density 
meter had to be rinsed 3 times with distilled water, and afterwards to pump air inside 
with a syringe 3 times as well. The last step was to engage the fan of the density 
meter which was “On” for approximately 15 minutes. This plays a significant role in 
the drying procedure (drying the tubes) of the density meter.  
The results of this measurement will be found in Chapter 7. (Table 1 and Table 2). 
6.3.3 Measurement of osmolality 
For measurement of osmolality,the osmometer had to be calibrated in first place, 
according to Ph. Eur. 8.0 2013. To perform the calibration reference solutions of 
sodium chloride with ideal osmolalities 100, 200, 300, 400, 500, 600, and 700 
mOsmol/kg had to be prepared. Then the real osmolalities were determined by using 
the equipment. Finally,the calibration equation was expressed to convert the 
measurement results of mos (mOsmol/kg) to the ideal osmolalities (mOsmol/kg). 
The 1
st
calibration equation with coefficient of determination R
2
 = 0.9998 is: 
y = 0.9684 x + 2.2         (7) 
where y = the measured mos and  x = the ideal mos 
The 2
nd
 calibration equation with coefficient of determination R
2
 = 0.9998 is: 
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y = 1.002381 x + 0.166667        (8) 
where y = the measured mos and  x = the ideal mos 
In order to check the equipment at every day measurement, first,the checking was 
done with water (0 mOsm/kg). 150μl of water were put in the clean, dry glass vessel 
with a pipette, was let to cool before the measurement started. After the water, one 
more check was performed with a standard solution (400 mOsm/kg). After those 
procedures were done, it was time to measure the osmolality of the samples. 
150μl of the sample were introduced to the osmometervessel and waited for 
approximately 1 minute until the temperature equilibrium of the sample solution was 
achieved. Then, the measurement started by pushing the Start button. After the 
measurement was finished, some waiting was needed for the sample to defreeze, and 
afterwards it had to be mixed (with a special vibration device, inside the osmometer) 
and repeat the measurement (5 times for each sample).  
When switching from one sample to another, it is required to wash with distilled 
water and then dry the measuringhead of the osmometer and the glass wessel where 
the sample was placed.  
The results of this measurement will be found in Chapter 7. (Table 3 and Table 4). 
6.4 Manipulation of results 
6.4.1 Conversion molality to molarity 
To convert molality m (mol/kg) to molarity c (mol/l), I divided the molality with the 




c             (9) 
The results of this measurement will be found in Chapter 7 in Table 5 and Table 6 for 
sodium chloride and potassium chloride, respectively. 
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6.4.2 Estimation of partial specific volume 
The partial specific volume Vgof a solute, is defined as a volume change of a solution 
when an additional 1g of a solute is dissolved in it (USP 35/NF 30 2011; ). 








           (10) 
Where Vg is the partial specific volume in ml/g, V is the volume of the solution in 
ml, Vw is the volume of water in ml and M₀ is the mass of the solute in g. 
The results of this measurement will be found in Chapter 7 Table 5/Figure 5 and 
Table 6/Figure 7 for sodium chloride and potassium chloride, respectively. 
6.4.3 Estimation of molal volume 
Molal volume Vmol (ml/mol) is the volume of 1 mol of a solvent at specific 
temperature and pressure conditions. The molal volume can be calculated similarly 





          (11) 
Where Vmolis the molal volume in ml/mol, V is the volume of the solution in ml, Vw 
is the volume of water in ml and m is the molality of the solvent in mol/kg. 
The results of this measurement will be found in Chapter 7 Table 5/Figure 6 and 
Table 6/Figure 8 for sodium chloride and potassium chloride, respectively. 
6.4.4 Estimation of molal osmotic coefficient 
The molal osmotic coefficient expresses the deviation of a solution from ideal 
behavior. The molal osmotic coefficient can be calculated by the following equation 





           (12) 
Where Φmis the molal osmotic coefficient, mos is the osmolality (osm/kg), υ is the 
number of particles formed by dissociation of one molecule (in the case of sodium 
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chloride and potassium chloride, this value is equal to 2), and m is the molality in 
mol/kg. 
The results of this measurement will be found in Chapter 7 Table 7/Figure 9 and 
Table 8/Figure 10 for sodium chloride and potassium chloride, respectively. 
6.4.5 Conversion osmolality to osmolarity 
The osmolarity cos(osmol/l), can be calculated in three different ways (USP 35/NF 30 
2011). 
One of them is the theoretical osmolarity (see Eq. 4) and takes in consideration only 
the number of particles formed by dissociation of a molecule (in the case of sodium 
chloride and potassium chloride, this value is equal to 2), and the molar 
concentration c (mol/l). 
Osmolaritycos (osmol/l) can also be calculated by the experimentally determined 
osmolalitymos (osmol/kg) and the partial specific volume of substance Vg(ml/g), by 
the equation (5) (unless the solution is very concentrated): 
Last but not least, osmolaritycos can be calculated by the so called “water 
contentmethod” according to the equation (6). 
The results of osmolarity estimation will be found in Chapter 7 Table 7/Figure 11 




Table 1: Results of density measurements of sodium chloride solutions 
m (mol/kg) Results of density Average SD 
0.01 0.9986 0.9986 0.9986 0.9986 0.9986 0.9986 0.00 
0.02 0.9990 0.9990 0.9990 0.9990 0.9990 0.9990 0.00 
0.03 0.9995 0.9995 0.9995 0.9995 0.9995 0.9995 0.00 
0.04 0.9999 0.9999 0.9999 0.9999 0.9999 0.9999 0.00 
0.05 1.0003 1.0003 1.0003 1.0003 1.0003 1.0003 0.00 
0.06 1.0007 1.0007 1.0007 1.0007 1.0007 1.0007 0.00 
0.07 1.0011 1.0011 1.0011 1.0011 1.0011 1.0011 0.00 
0.08 1.0015 1.0015 1.0015 1.0015 1.0015 1.0015 0.00 
0.09 1.0019 1.0019 1.0019 1.0019 1.0019 1.0019 0.00 
0.10 1.0023 1.0023 1.0023 1.0023 1.0023 1.0023 0.00 
0.50 1.0185 1.0185 1.0185 1.0185 1.0185 1.0185 0.00 
1.00 1.0378 1.0378 1.0378 1.0378 1.0378 1.0378 0.00 
 
Table 2: Results of density measurements of potassium chloride solutions 
m 
(mol/kg) 
Results of density Average SD 
0.01 0.9987 0.9987 0.9987 0.9987 0.9987 0.9987 0.00 
0.02 0.9992 0.9992 0.9992 0.9992 0.9992 0.9992 0.00 
0.03 0.9996 0.9996 0.9996 0.9996 0.9996 0.9996 0.00 
0.04 1.0001 1.0001 1.0001 1.0001 1.0001 1.0001 0.00 
0.05 1.0006 1.0006 1.0006 1.0006 1.0006 1.0006 0.00 
0.06 1.0011 1.0011 1.0010 1.0010 1.0010 1.00104 0.00 
0.07 1.0015 1.0015 1.0015 1.0015 1.0015 1.0015 0.00 
0.08 1.0020 1.0020 1.0020 1.0020 1.0020 1.002 0.00 
0.09 1.0025 1.0025 1.0025 1.0025 1.0025 1.0025 0.00 
0.10 1.0029 1.0029 1.0029 1.0029 1.0029 1.0029 0.00 
0.50 1.0211 1.0211 1.0211 1.0211 1.0211 1.0211 0.00 





Figure 1: Graph showing the connection between density-molality for sodium chloride 
 
 






Table 3: Results of osmolality measurements of sodium chloride 
m 
(mol/kg) 
Results of osmolality Average SD Ideal mos 
0.01 19 19 19 20 19 19.2 0.45 17.6 
0.02 38 38 38 38 37 37.8 0.45 36.8 
0.03 57 57 58 58 58 57.6 0.55 57.2 
0.04 73 74 71 74 75 73.4 1.52 73.5 
0.05 93 94 92 93 94 93.2 0.84 94.0 
0.06 113 114 112 115 113 113.4 1.14 114.8 
0.07 130 134 135 134 134 133.4 1.95 135.5 
0.08 150 144 151 150 153 149.6 3.36 152.2 
0.09 170 167 168 169 168 168.4 1.14 171.6 
0.10 175 180 178 180 178 178.2 2.05 181.7 
0.50 888 909 906 902 906 902.2 8.32 929.3 
1.00 1763 1764 1772 1777 1780 1771.2 7.60 1826.7 
 
Table 4: Results of osmolality measurements of potassium chloride 
m 
(mol/kg) 
Results of osmolality Average SD Ideal mos 
0.01 20 20 20 19 20 19.8 0.45 19.6 
0.02 38 40 39 39 40 39.2 0.84 38.9 
0.03 57 58 57 57 56 57.0 0.71 56.7 
0.04 77 77 77 75 77 76.6 0.89 76.3 
0.05 93 94 95 95 96 94.6 1.14 94.2 
0.06 115 115 115 115 115 115 0.00 114.6 
0.07 131 129 128 131 131 130 1.41 129.5 
0.08 152 151 152 152 150 151.4 0.89 150.9 
0.09 170 171 167 167 170 169 1.87 168.4 
0.10 187 188 186 187 188 187.2 0.84 186.6 
0.50 884 882 881 882 880 881.8 1.48 879.5 
1.00 1716 1722 1716 1722 1722 1719.6 3.29 1715.3 
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Figure 3: The relationship between osmolality-molality for sodium chloride 
 
 





Table 5: The properties of sodium chloride solutions 
m 
(mol/kg) 






0.01 0.5844 1000.5844 0.9986 1001.9872 0.0100 0.31 18.39 
0.02 1.1688 1001.1688 0.9990 1002.1710 0.0200 0.31 18.39 
0.03 1.7532 1001.7532 0.9995 1002.2543 0.0299 0.26 15.04 
0.04 2.3376 1002.3376 0.9999 1002.4378 0.0399 0.27 15.86 
0.05 2.9220 1002.9220 1.0003 1002.6212 0.0499 0.28 16.36 
0.06 3.5064 1003.5064 1.0007 1002.8044 0.0598 0.29 16.69 
0.07 4.0908 1004.0908 1.0011 1002.9875 0.0698 0.29 16.92 
0.08 4.6752 1004.6752 1.0015 1003.1704 0.0797 0.29 17.09 
0.09 5.2596 1005.2596 1.0019 1003.3532 0.0897 0.29 17.22 
0.10 5.8440 1005.8440 1.0023 1003.5359 0.0996 0.30 17.33 
0.50 29.2200 1029.2200 1.0185 1010.5253 0.4948 0.30 17.44 
1.00 58.4400 1058.4400 1.0378 1019.8882 0.9805 0.31 18.08 
 
Table 6: The properties of potassium chloride solutions 
m 
(mol/kg) 




0.01 0.7455 1000.7455 0.9987 1002.0482 0.010 0.33 24.49 
0.02 1.4910 1001.4910 0.9992 1002.2928 0.020 0.33 24.48 
0.03 2.2365 1002.2365 0.9996 1002.6376 0.030 0.37 27.81 
0.04 2.9820 1002.9820 1.0001 1002.8817 0.040 0.36 26.96 
0.05 3.7275 1003.7275 1.0006 1003.1256 0.050 0.35 26.45 
0.06 4.4730 1004.4730 1.00104 1003.4294 0.060 0.36 27.10 
0.07 5.2185 1005.2185 1.0015 1003.7129 0.070 0.37 27.28 
0.08 5.9640 1005.9640 1.002 1003.9561 0.080 0.36 26.91 
0.09 6.7095 1006.7095 1.0025 1004.1990 0.090 0.36 26.62 
0.10 7.4550 1007.4550 1.0029 1004.5418 0.100 0.37 27.39 
0.50 37.2750 1037.2750 1.0211 1015.8408 0.492 0.38 28.08 







Figure 5: Graph showing the connection between partial specific volume (Vg) and molality 
for sodium chloride 
 
Figure 6: Graph showing the connection between molal volume (Vmol) and molality 










Figure 7: Graph showing the connection between partial specific volume (Vg) and 
molality for potassium chloride 
 
 
Figure 8: Graph showing the connection between molal volume (Vmol) and molality 




Table 7: Approximation of osmolarity of sodium chloride solutions 
   cos (mOsmol/l) 




0.01 19.2 0.960 20.0 17.5 17.5 
0.02 37.8 0.945 39.9 36.7 36.7 
0.03 57.6 0.960 59.9 57.1 57.1 
0.04 73.4 0.918 79.8 73.4 73.3 
0.05 93.2 0.932 99.7 93.9 93.7 
0.06 113.4 0.945 119.7 114.8 114.5 
0.07 133.4 0.953 139.6 135.5 135.1 
0.08 149.6 0.935 159.5 152.2 151.7 
0.09 168.4 0.936 179.4 171.7 171.0 
0.10 178.2 0.891 199.3 181.8 181.1 
0.50 902.2 0.902 989.6 938.2 919.4 
1.00 1771.2 0.886 1961.0 1860.8 1789.2 
 
 
Table 8: Approximation of osmolarity of potassium chloride solutions 
   cos (mOsmol/l) 
m (mol/kg) mos(mOsmol/kg) Φm Theoretical 
(Eq.4) 
Experimental 
(VgEq.5) (w.t. Eq.6) 
0.01 19.8 0.990 20.0 19.6 19.5 
0.02 39.2 0.980 39.9 38.9 38.9 
0.03 57 0.950 59.8 56.6 56.5 
0.04 76.6 0.958 79.8 76.2 76.0 
0.05 94.6 0.946 99.7 94.1 93.9 
0.06 115 0.958 119.6 114.5 114.2 
0.07 130 0.929 139.5 129.5 129.0 
0.08 151.4 0.946 159.4 150.9 150.3 
0.09 169 0.939 179.2 168.4 167.7 
0.10 187.2 0.936 199.1 186.6 185.7 
0.50 881.8 0.882 984.4 885.4 865.4 














Figure 10: Graph showing the connection between molal osmotic coefficient Φm-





Figure 11: Relationship between osmotic concentrations and molality for sodium chloride 




Figure 12: Relationship between osmotic concentrations and molality for potassium 
chloride(cos (1) is calculated by Eq. 4, cos (2) is calculated by Eq. 5, and cos (3) is calculated 





The importance of the osmotic effects in the organism is very big because they are 
responsible for maintaining the human body homeostasis. More specific, osmotic 
pressure is very significant for all biological processes that involve fluid transfer 
through biological membranesand therefore maintaining the “tone” of the cells; this 
includes a specific biological concentration of ions, molecules, and aggregated 
species that give the cells specific properties. 
In this experimental work aqueous solutions of sodium chloride and potassium 
chloride were prepared in different molality concentrations in a range of 0.01 – 1.00 
mol/kg. Those solutions were used to measure their density and molality in a 
procedure that was described above in this text. The results that were obtained from 
those measurements were used to convert molality to molarity as well as osmolality 
to osmolarity. 
The results are summarized in Tables 1 – 8 and Figures 1 – 12. In the figures, only 
the results in a concentration range of 0.01 – 0.10 mol/kg are presented, because it 
was difficult to plot them all in the same graph, due to the large difference in scale. 
Density 
The density was measured with a density meter the principle of which is measuring 
the frequency of oscillation. The results are summarized in Tables (1) and (2). The 
relationship between molality m (mol/kg) and density d (g/ml) follows a simple 
proportion that can be seen on Figures (1) and (2), respectively. The results were in 
accordance to the theory. 
From those results it was also possible to generate the equations for both sodium 
chloride and potassium chloride that show this relationship. For sodium chloride the 
equation with coefficient of determination (R
2
 = 0.9995) is:  
9982.00411.0  md         (13)  




9982.00471.0  md         (14)  
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Using the equations, it is possible to calculate any density value (y axis) for any 
molality value (x axis) within the range from 0.00 mol/kg to 1.00 mol/kg. 
Osmolality 
Osmolality was measured with an osmometer by measuring the freezing point 
depression. The measured results obtained were converted into the ideal osmolality 
using the calibration equation shown in the Experimental section. In fact, the 1
st
 
calibration equation was used for sodium chloride while the 2
nd
 one for potassium 
chloride, respectively. The reason was that calibration should be repeated at any time 
of change of measuring vessel. This was true for the second substance. 
The results of osmolality values are summarized in Tables (3) and (4). The 
relationship between molality m (mol/kg) and osmolalitymos (mOsmol/kg), similarly 
to molality-density connection, follows a simple proportion that can be seen on 
Figures (3) and (4). No deviation from theory was observed. 
From those results, again, it was possible to calculate the equations relating molality 
to osmolality for both sodium chloride and potassium chloride. For sodium chloride, 
the relationship between molality m (mol/kg) and osmolality mos(mOsmol/kg) could 
be described by equation with the coefficient of determination R
2
 = 0.9981: 
5273.16.1831  mmos         (15) 
Similar equation with coefficient of determination R
2
 = 0.9997, was detected for 
potassium chloride: 
1727.11.1867  mmos         (16) 
By using the equations it is possible to calculate and later see on the graphs the ideal 
osmolality values, for any molality value within the range 0.01mol/kg to 1.00 
mol/kg. 
Conversion molality to molarity 
In order to convert molality to molarity, first, the volume V (ml) of the solution had 
to be calculated, using the experimentally estimated density and thenmolality m 
(mol/kg) was converted to molarity c (mol/l) using the equation (9). 
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The results are presented in Table 5 and Table 6.It could be seen that the differences 
between the values of concentration are small for very diluted solutions and could be 
neglected but they increase when concentration increases. 
From the practical point of view, preparation of solutions in molality way is 
easierbecausethe temperature calibration is not required. The conversion of molality 
to molarity is necessary to express theoretical osmolarity (see below). 
Estimation of the partial specific volume and molal volume of substance 
Some of the additional information that were alsoestimated were the partial specific 
volume Vg (ml/g) and molal volume Vmol (ml/mol) from the equations (10) and (11), 
respectively.Those values can be seen analytically in Table 5 and Table 6. The 
influence of molality on the Vg and Vmolvalues is shown in Figures 5 - 8. It could be 
seen that the values vary around the average value from the concentration of 
approximately 0.03 mol/kg up to 1.00 mol/kg. In Figures, therefore, the average 
value is signed by a line. In opposite, the values of Vg and Vmol decreasewhen 
concentration reaches the infinite dilution, i.eat very low concentrations of 0.01 
mol/kg and 0.02 mol/kg. 
The average Vg and Vmolvalues for sodium chloride are 0.29 ml/g and 16.80 ml/mol, 
respectively, while the average values for potassium chloride are 0.36 ml/g and 26.80 
ml/mol, respectively. Similar results were previously presented by Storkova (2014) 
with the average values of Vg and Vmol0.30 ml/g and 17 ml/mol for sodium chloride 
and 0.37 ml/g and 27 ml/mol for potassium chloride, respectively. The molal 
volumes of both substances at infinite dilution of 16.63 ml/mol for NaCl and 26.74 
ml/mol for KCl were estimated (Streng et al. 1978). The values of Vmol were close to 
the experimental results of this thesis. 
Estimation of molal osmotic coefficient Φm 
Molal osmotic coefficient Φm is one more value that was also possible to be 
calculated from the previously estimated osmolality mos according to the equation 
(12). That value should be close to 1 (but not over 1) and it decreases as the 
concentration increases. Those results can be found on Table 7, Table 8 and on 
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Figure 9 and Figure 10.The value of Φm decreases if concentration increases (USP 
35/NF 30 2011; Ph. Eur. 8.3). The results noted complied to the theory. 
Approximation of osmolarity 
To expect the osmotic effect of parenteral infusions, osmolarity value is required. 
Unfortunately, osmolarity cannot be measured. To express the values of osmolarity 
cos (osmol/l), the calculation is required. It is possible to calculate the osmolarity 
values from 3 different equations (USP 35/NF 30 2011).  
One is the calculation of the theoretical osmolarity (Eq. 4) from the molarity of the 
solution. Thus, the conversion from molality to molarity, which requires 
measurement of the solution density, is necessary. The other onesare calculation of 
osmolarity from the exeprimentally determined Vg(Eq. 5) and/or “water 
contentmethod” (Eq. 6). The method of approximation is described above in 
Theoretical section (5.2.2) and Experimental section.The results can be found in 
Table 7 and Table 8 and on Figure 11 and Figure 12.Although the differences 
between measured osmolality and the estimated osmolarity are very low, below 
concentration limit of 0.1 mol/kg, they increase when concentration approaches 1 
mol/kg. The theoretical approximation is the least accurate as could be seen in 
Figures 11 and 12. It can only describe an ideal behaviour of a substance where its 
particles don not interact with each other. According to the results from the three 
different methods, the most precise way to determine osmolarity is by using the 
experimentally determined density and osmolality followed by employing the partial 




From the results of this thesis the following conclusions were drawn: 
1. The relationship between molality and density as well as between molality 
and osmolality follow the simple proportion in which both variables increase 
if concentration raises. 
2. The average values of Vg and Vmolfor sodium chloride of 0.29 ml/g and 16.80 
ml/mol, respectively, and 0.36 ml/g and 26.84 ml/mol for potassium chloride, 
respectively, were experimentally detected. 
3. To convert molality to molarity,the density of the solution is necessary to be 
determined. 
4. The molal osmotic coefficient m decreases steadily when molality increases. 
5. To estimate osmolarity with the highest accuracy, the method using the 
partial specific volume Vg and/or the "water content" can be recommended 
for soduim chloride and potassium chloride. 
6. To convert osmolality to osmolarity precisely, the density of the solution and 
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